Find a Clinical Trial

Showing 1 - 10 of 316 Trials

A randomized controlled double-blind comparison of placebo, pulsed-electromagnetic field device, and pectoral block in mastectomy and reconstruction patients

Principal Investigator:

Christine H. Rohde, MD, MPH, FACS

Contact Number:

(212) 342-5162

NCT Number:

NCT03360214

Population:

Adult

Phase:

IV

Pain after surgery is common, and it not only affects the post-operative patient experience but is also associated with development of chronic pain and delayed wound healing. Narcotic pain medications are usually prescribed after surgery, but they have many side effects. There are two types of non-narcotic pain control techniques currently in use at Columbia University Irving Medical Center (CUIMC). The first mode uses pulsed electromagnetic fields (PEMF). It is a painless device placed over dressings around the surgical site. The second type of technique uses a numbing medication called...
Head Start 4: Newly Diagnosed Children (Less Than 10 Years Old) With Medulloblastoma and Other Central Nervous System Primitive Neuro-Ectodermal Tumors: Clinical and Molecular Risk-Tailored Intensive and Compressed Induction Chemotherapy Followed By

Principal Investigator:

James Hinkley Garvin Jr, MD

Contact Number:

(212) 342-5162

NCT Number:

NCT02875314

Population:

Pediatrics

Phase:

IV

This is a prospective randomized clinical trial, to determine whether dose- intensive tandem Consolidation, in a randomized comparison with single cycle Consolidation, provides an event-free survival (EFS) and overall survival (OS). The study population will be high-risk patients (non-Wnt and non-Shh sub-groups) with medulloblastoma, and for all patients with central nervous system (CNS) embryonal tumors completing Head Start 4 Induction. This study will further determine whether the additional labor intensity (duration of hospitalizations and short-term and long-term morbidities) associated...
A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative

Principal Investigator:

Eileen P. Connolly, MD, PhD

Contact Number:

(212) 342-5162

NCT Number:

NCT01872975

Population:

Adult

Phase:

III

• The main purpose of this clinical trial is to study women like you who have cancer cells in the lymph nodes at the time that the breast cancer is diagnosed and have chemotherapy before surgery that clears the cancer cells from the lymph nodes. This study asks 1) if, after lumpectomy, radiation to the breast and lymph nodes will be better than radiation only to the breast at keeping breast cancer from returning, and 2) if, after mastectomy, radiation to the area where the breast used to be and to the lymph nodes is better than no radiation at keeping breast cancer from returning...
A randomized phase III trial evaluating the role of axillary lymph node dissection in breast cancer patients (cT1-3 N1) who have positive sentinel lymph node disease after neoadjuvant chemotherapy

Principal Investigator:

Bret Taback, MD

Contact Number:

(212) 342-5162

NCT Number:

NCT01901094

Population:

Adult

Phase:

III

Patients with your type of breast cancer usually have neoadjuvant (which means “given before surgery) chemotherapy followed by breast and arm pit surgery to remove any remaining breast cancer. The lymph nodes in the arm pit are examined during surgery and if there is still cancer in the lymph nodes, then the majority of lymph nodes in the arm pit are removed. The purpose of this study is to examine whether removing some of the lymph nodes from the arm pit, but not removing them all followed with radiation therapy (experimental) will be as good as having the majority of the lymph nodes...
ANBL1232: Utilizing Response and Biology Risk Factors to guide Therapy in Patients with Non-Risks Neuroblastoma

Principal Investigator:

Justine Kahn, MD, MS

Contact Number:

212-342-5162

NCT Number:

NCT02176967

Population:

Pediatrics

Phase:

III

This phase III study is looking at whether using certain risk factors and biomarkers (proteins and/or gene changes in tumor cells) to determine how much treatment a younger patient with non-high risk neuroblastoma should receive will allow for a decrease in treatment for these patients while still curing their neuroblastoma. For some patients, this may include no treatment and only close observation. Measuring biomarkers in tumor cells may help plan when effective treatment is necessary and what the best treatment is. This may help to avoid some of the risks and side effects related to...
A Phase 3, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Eflornithine with Lomustine Compared to Lomustine Alone in Patients with Anaplastic Astrocytoma That Progress/Recur After Irradiation and Adjuvant Temozolomide Chemotherapy

Principal Investigator:

Andrew B. Lassman, MD

Contact Number:

(212) 342-5162

NCT Number:

NCT02796261

Population:

Adult

Phase:

III

The purpose of this study is to measure how well and how safe eflornithine is in combination with lomustine, compared to lomustine taken alone, in treating patients whose anaplastic astrocytoma has come back after radiation and chemotherapy. Safety and how well you can tolerate the drug will be determined on the basis of physical exams, laboratory tests, and questions about any problems you might experience during the study. Are you Eligible? (Inclusion Criteria) Subject must be 18 years of age or older Subject must have a surgical or biopsy-proven diagnosis of WHO Grade 3 Anaplastic...
ARST1431 - A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864, IND# 122782) in Patients with Intermediate Risk (IR)

Principal Investigator:

Alice Lee, MD

Contact Number:

(212) 342-5162

NCT Number:

NCT02567435

Population:

Pediatrics

Phase:

III

This randomized phase III trial is studying how well standard chemotherapy (vincristine, dactinomycin, cyclophosphamide, and irinotecan) works compared to combination chemotherapy combined with temsirolimus (new agent) in treating patients with rhabdomyosarcoma (cancer that forms in the soft tissues, such as muscle) in patients with intermediate risk rhabdomyosarcoma. Are you Eligible? (Inclusion Criteria) Less than 21 years old at the time of study entry. Newly diagnosed with intermediate risk rhabdomyosarcoma. Patients can not have received any chemotherapy (excluding steroids) and/or...
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (>pN1mic) After Neoadjuvant Chemotherapy

Principal Investigator:

Meghna S Trivedi, MD

Contact Number:

(212) 342-5162

NCT Number:

NCT02954874

Population:

Adult

Phase:

III

The purpose of this study is to compare the usual approach (i.e. no more treatment or additional post-operative chemotherapy), to any effects, good and/or bad, of the experimental drug MK-3475 (also called pembrolizumab) after surgery. This study will allow the researchers to know whether treatment with MK-3475 (pembrolizumab) is better, the same, or worse than the usual approach. There will be about 1,000 people taking part in this study.
AGCT1531 - A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors

Principal Investigator:

Justine Kahn, MD, MS

Contact Number:

212-342-5162

NCT Number:

NCT03067181

Population:

Pediatrics/Adult

Phase:

III

This partially randomized phase III trial studies how well active surveillance, bleomycin, carboplatin, etoposide, or cisplatin work in treating pediatric and adult patients with germ cell tumors. Active surveillance may help doctors to monitor subjects with low risk germ cell tumors after their tumor is removed. Drugs used in chemotherapy, such as bleomycin, carboplatin, etoposide, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Are you Eligible? (Inclusion Criteria)...
An International, Phase 3, Open-label, Randomized Study of BGB-3111 Compared with Bendamustine plus Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Principal Investigator:

Nicole Lamanna, MD

Contact Number:

(212) 342-5162

NCT Number:

NCT03336333

Population:

Adult

Phase:

III

The purpose of this study is to compare the effects, good or bad, of the experimental drug BGB-3111, versus a known standard treatment called bendamustine plus rituximab (B+R) on you and your chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) to find out which is better. In this study you will receive either BGB-3111 or the standard chemotherapy treatment bendamustine plus rituximab (B+R). Are you Eligible? (Inclusion Criteria) To be eligible for this trial, participants must: Do you have a diagnosis of CLL or SLL? Are you at least 18 years old? Do you have adequate organ...

Find a Clinical Trial

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Pages